AFP and neoplasm: The TACE group included 27 patients (47.4% of the total), including 19 males (70.4%) and 8 females (29.6%) with a mean age of 73 ± 8.43 years (range: 40–86 years); 3 were in Child class A and 24 in Child class B. In the TACE group, mean pre-treatment serum AFP level was 345.58 ± 1175.90 ng/mL (range 2.2–6000 ng/mL); mean pre-treatment tumor size was 33.07 ± 18.02 mm (range: 10–76 mm); and mean post-treatment serum AFP level was 91.85 ± 143.75 ng/mL (range: 2.1–546 ng/mL).